

SYFOVRE[®]
(pegcetacoplan injection)
15 mg / 0.1 mL

EFFECTIVE OCTOBER 1, 2023

Permanent J-code for SYFOVRE: **J2781**

Product Ordering Guide

ApellisAssist[™] **Here for your patients**

Phone: **888-APELLIS** (888-273-5547) 8 AM-8 PM ET, Monday-Friday

Website: SyfovreECP.com

Portal: ApellisAssistGA.com

Fax: **888-405-6966**

INDICATION

SYFOVRE[®] (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

➤ Please see additional Important Safety Information throughout and the full [Prescribing Information](#).

Apellis

Product information at a glance

Indication¹	SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
How Supplied¹	A clear, colorless to light yellow aqueous solution.
Packaging¹	Each SYFOVRE carton contains one single-dose glass vial.
Ancillary Supplies¹	The following supplies are required to administer SYFOVRE: <ul style="list-style-type: none"> • One 5-micron filter needle (included in the IVT Injection Kit) • One 1-mL Luer-lock syringe with a 0.1 mL dose mark (not included) • One ½ inch, 29-gauge thin-wall injection needle with Luer-lock hub (included in the IVT Injection Kit) or 27-gauge needle with Luer-lock hub (not included) • Alcohol swab (not included)
Recommended Dosage¹	15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days .
Storage Requirements¹	<ul style="list-style-type: none"> • Refrigerate between 2 °C to 8 °C (36 °F to 46 °F) • Store the vial in the original carton to protect from light • Do not use beyond the expiration date on the carton • Keep the vial in the original carton at room temperature for at least 15 minutes prior to injection, but no longer than 8 hours



Approval date²	2/17/23
----------------------------------	---------

ICD-10-CM Codes for GA ³	Nonexudative age-related macular degeneration (AMD)	Right eye	Left eye	Bilateral
		Advanced atrophic without subfoveal involvement	H35.3113	H35.3123
	Advanced atrophic with subfoveal involvement	H35.3114	H35.3124	H35.3134
CPT Code⁴	67028: Intravitreal injection of a pharmacologic agent, separate procedure			
HCPCS Code⁵	Permanent J-code^{a,b} effective October 1, 2023	Site of care		
	J2781: Injection, pegcetacoplan, intravitreal, 1 mg Bill 15 units for each SYFOVRE injection	Physician office and hospital outpatient		
NDC¹	10-digit NDC: 73606-020-01	11-digit NDC: 73606-0020-01		

The coding information in this document is provided for informational purposes only, is subject to change, and should not be a substitute for independent clinical judgment when selecting diagnosis and/or reimbursement codes. Codes listed above may not be exhaustive of those required by payers.

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision; NDC=National Drug Code.

^a J2781 is a permanent, product-specific code assigned by CMS. Bill 15 units for each SYFOVRE injection.

^b Dose descriptor is assigned by CMS; please see full prescribing information for approved dosing.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments

- Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.



Please see additional Important Safety Information throughout and the full Prescribing Information.

SYFOVRE
(pegcetacoplan injection)
15 mg/0.1 mL

Ordering information

SYFOVRE is available through 2 distribution channels

1. Specialty distributors for buy and bill

AmerisourceBergen (Besse Medical)

Phone: 800-543-2111
Fax: 800-543-8695
Email: service@besse.com
besse.com/contact-us

CuraScript® SD

Phone: 877-599-7748
Fax: 800-862-6208
Email: Customer.Service@curascript.com
order.curascriptsd.com

Cardinal Health™ (Metro Medical™)

Phone: 800-768-2002 (Monday-Friday, 8 AM-8 PM ET)
Email: customersvc@cardinalhealth.com
metromedicalorder.com

McKesson Specialty Health for Physician Clinics

Phone: 855-477-9800
Fax: 800-800-5673
Email: mshcustomer-care-mspl@mckesson.com
mscs.mckesson.com

McKesson Plasma & Biologics for Health Systems and Hospitals

Phone: 877-625-2566
Fax: 888-752-7626
Email: mpborders@mckesson.com
connect.mckesson.com

2. Specialty pharmacies

Accredo® Specialty Pharmacy

Phone: 800-803-2523
(Monday-Friday, 8 AM-8 PM ET)
Fax: 888-302-1028 (to fax a referral)
E-prescribing is also available.
accredo.com

Optum Specialty Pharmacy

Phone: 855-427-4682 (available 24/7)
Fax: 877-342-4596
specialty.optumrx.com

CenterWell Specialty Pharmacy™

Phone: 800-486-2668
(Monday-Friday, 8 AM-11 PM ET)
Fax: 877-405-7940
E-prescribing is also available.
Select "CenterWell Specialty Pharmacy" in e-prescribing software.
centerwellspecialtypharmacy.com

Apellis does not recommend the use of any particular listed distributor or pharmacy.

Buy and bill or specialty pharmacy?

SYFOVRE can be acquired through buy and bill or a specialty pharmacy. Consider the factors below with your practice in mind to help select an appropriate acquisition method.

	Buy and Bill	Specialty Pharmacy (SP)
Payer	Required by Medicare Fee-for-Service (FFS)	May be required by some payers
Ordering and Shipment	SYFOVRE purchased from specialty distributor and shipped to office	<ul style="list-style-type: none"> • Prescription enrollment form sent to SP • Benefits verified and patient out-of-pocket (OOP) costs collected and processed by SP prior to shipping • SYFOVRE shipped from SP to office
Inventory	Stock of SYFOVRE maintained by office to be used any time	SYFOVRE to be used only for patient listed on shipment

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

• Retinal Vasculitis and/or Retinal Vascular Occlusion

- Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.



Please see additional Important Safety Information throughout and the full Prescribing Information.

SYFOVRE
(pegcetacoplan injection)
15 mg / 0.1 mL



SYFOVRE[®]

(pegcetacoplan injection)
15 mg / 0.1 mL

INDICATION

SYFOVRE[®] (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments

- Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

• Retinal Vasculitis and/or Retinal Vascular Occlusion

- Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.

• Neovascular AMD

- In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

• Intraocular Inflammation

- In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

• Increased Intraocular Pressure

- Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

- Most common adverse reactions (incidence $\geq 5\%$) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full [Prescribing Information](#) for more information.

References: **1.** Syfovre. Prescribing information. Apellis Pharmaceuticals, Inc.; 2023. **2.** NDA Approval 217171. US Food and Drug Administration. February 17, 2023. Accessed July 18, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217171Orig1s000ltr.pdf **3.** Lum F, Repka MX, Vicchilli S. How to use the ICD-10 codes for age-related macular degeneration. *EyeNet Magazine*. 2017;9:61–62. **4.** Coding for injectable drugs. American Academy of Ophthalmology. Accessed July 18, 2023. <https://www.aao.org/practice-management/coding/injectable-drugs> **5.** Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations. Centers for Medicare & Medicaid Services. Accessed August 14, 2023. <https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-2-2023-drugs-and-biologicals.pdf>